Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer

By B. Tran, S. Kopetz, J. Tie, P. Gibbs, Zhi-qin Jiang, Christopher H Lieu, A. Agarwal, D. Maru, O. Sieber, J. Desai. Cancer, 2011

764 citations recorded by the source corpus.

It is hypothesized that BRAF mutant cancers represent a discrete subset of metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates whether BRAF mutant CRC is further defined by a distinct pattern of metastatic spread and explores the impact of BRAF mutation and microsatellite instability (MSI) on prognosis in metastatic CRC.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0fa33ed53ef5ad61713666a8f65595d9d56269fb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. René Bernards
2. R. Salazar
3. Justin Guinney
4. A. Bardelli
5. Jean-Pierre Issa
6. Joe W. Gray
7. Jeffrey S. Morris
8. Charlotte Soneson

In Oncology

1. René Bernards
2. Jean-Pierre Issa
3. Joe W. Gray
4. Jeffrey S. Morris
5. Louis Vermeulen
6. Fortunato Ciardiello
7. E. Fessler
8. J. Medema

In Pulmonary and Respiratory Medicine

1. F. Janku
2. D. Hanahan

Citations in the corpus

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “[60] reported a median survival for patients with BRAF-mutant mCRC of 10.”
• Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015, background): “Patients with metastatic BRAF-mutated CRC have a poor prognosis, with a median survival of approximately 12 months despite the utilization of combination chemotherapy.(6) The mutation of a valine to glutamate in codon 600 in the BRAF kinase domain (V600E) results in a constitutively active protein.”
• The Consensus Molecular Subtypes of Colorectal Cancer (2015, methodology): “is supported by grants from the Dutch Cancer Society (UVA2011-4969, UVA2014-7245), Worldwide Cancer Research (14-1164), the Maag Lever Darm Stichting (MLDS-CDG 14-03) and the European Research Council (ERG-StG 638193).”